Table 3 Univariate and multivariate Cox proportional hazards regression analysis for DFS

Age (years) (< 44 vs. ≥44)

1.241 (0.626–2.459)

0.536

HPV DNA (pg/ml) (< 1 vs. ≥1)

0.659 (0.087–4.978)

0.686

FIGO stage (≤IIA vs. ≥IIB)

1.797 (0.630–5.128)

0.273

Pathological type (SCNEC -alone vs. SCNEC -mix)

1.455 (0.685–3.092)

0.330

Pre-operative Chemotherapy (No vs. Yes)

0.841 (0.408–1.733)

0.638

Post-operative Chemotherapy (No vs. Yes)

0.372 (0.113–1.224)

0.104

Post-operative Radiotherapy (No vs. Yes)

0.790 (0.398–1.565)

0.499

Tumor size (cm) (< 2 vs. 2–4 vs. ≥4)

1.132 (0.675–1.899)

0.637

Stromal invasion (<  1/2 vs. ≥1/2)

1.382 (0.660–2.892)

0.391

Endometrial invasion (No vs. Yes)

1.136 (0.347–3.722)

0.833

Parametrium invasion (No vs. Yes)

2.359 (0.910–6.119)

0.077

CIN (No vs. Yes)

1.171 (0.509–2.696)

0.711

LNM (No vs. Yes)

1.071 (0.536–2.141)

0.845

Nerve invasion (No vs. Yes)

2.707 (1.310–5.594)

0.007

LVI (No vs. Yes)

2.061 (0.928–4.576)

0.076

N-marker (≤2+ vs. > 2+)

1.472 (0.449–4.828)

0.523

MMR (pMMR vs. dMMR)

0.039 (0.001–2.416)

0.123

Ki67 (< 60 vs. ≥60%)

3.244 (0.777–13.551)

0.107

SOX2 (Low vs. High)

2.401 (1.044–5.524)

0.039

P16^INK4A (− vs. +)

2.246 (0.685–7.366)

0.182

HR-HPV RISH (− vs. +)

4.309 (1.019–19.208)

0.047

SOX2/ P16^INK4A (AI vs. AII vs. AIII)

2.123 (1.108–4.067)

0.023

SOX2/ HR-HPV RISH (BI vs. BII vs. BIII)

3.220 (1.532–6.771)

0.002